Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2010-02-19 Capital/Financing Update
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
8-K Filing
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The content describes the closing of a public offering of common stock and the exercise of an over-allotment option, including details about the number of shares and net proceeds. This is an update on the company's financing activities. The document is relatively short (2379 characters) and includes a press release as an exhibit. The primary focus is on capital raising and financing, not a full financial report or earnings release. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2010-02-19 English
424B1 Filing
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus for a public offering of 5,000,000 shares of common stock by NeoStem, Inc. It includes extensive information about the company, its business segments, market opportunities, risk factors, use of proceeds, and other disclosures typical of a securities offering document. The presence of underwriting details, risk factors, use of proceeds, and detailed business description confirms this is a prospectus related to a capital raising event. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. The document is not an annual or quarterly report, audit report, or any other type of filing listed. Therefore, the correct classification is CAP with high confidence.
2010-02-12 English
8-K Filing
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to a public offering of common stock, including underwriting details and an over-allotment option. It also references a press release about the pricing of the offering. There are no financial statements or detailed financial results presented, only an announcement of financing activity. The document length is 3479 characters, which is relatively short and consistent with a current report announcement rather than a full financial report. Therefore, this filing is best classified as a Capital/Financing Update (CAP).
2010-02-12 English
S-1/A Filing
Capital/Financing Update Classification · 100% confidence The document is a "Pre-Effective Amendment No. 4 to FORM S-1" filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for NeoStem, Inc. The document includes a preliminary prospectus for a public offering of common stock, detailing the offering size, price, underwriting, risk factors, business description, and other related information. This type of filing is related to capital raising activities and securities registration for an initial or follow-on public offering. It is not an annual report, earnings release, or management discussion, but rather a registration statement for securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2010-02-11 English
SC 13G Filing
Major Shareholding Notification
2010-02-10 English
S-1/A Filing
Capital/Financing Update Classification · 100% confidence The document is a Pre-Effective Amendment No. 3 to Form S-1 filed with the U.S. Securities and Exchange Commission. Form S-1 is a registration statement used for securities offerings under the Securities Act of 1933. The document includes detailed information about the registration, underwriting agreements, legal opinions, and exhibits related to the securities offering. It is not an annual report, earnings release, or any other financial report but rather a capital raising registration statement. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains substantive content related to the offering, not just an announcement or certification.
2010-02-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.